Epidermal Growth Factor Receptor (EGFR) Status Based Gefitinib Neoadjuvant Therapy in Non Small Cell Lung Cancer (NSCLC)

• Status: Suspended
• Trial end date: 2016-11-01
• Target enrollment: 0
• Participant gender: All

Summary

This study aims to investigate the efficacy and safety of gefitinib as neoadjuvant therapy in stage IIIA NSCLC patients.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital
• Treatments: Gefitinib

Criteria

Inclusion Criteria:

• Patients pathological diagnosed with NSCLC,with EGFR sensitive mutation;

• Stage IIIA patients with technical operable disease evaluated by image and lab results;

• Patients without chemotherapy or targeted-therapy before;

• Inform Consent.

Exclusion Criteria:

• Patients with malignant tumor other than lung cancer;

• Patients with other diseases such as cardiovascular disease that may hamper follow up;

• Patients that may not coordinate well,judged by researcher.